290 related articles for article (PubMed ID: 23032069)
1. ABCG2 protects kidney side population cells from hypoxia/reoxygenation injury through activation of the MEK/ERK pathway.
Liu WH; Liu HB; Gao DK; Ge GQ; Zhang P; Sun SR; Wang HM; Liu SB
Cell Transplant; 2013; 22(10):1859-68. PubMed ID: 23032069
[TBL] [Abstract][Full Text] [Related]
2. ERK/MAPK activation involves hypoxia-induced MGr1-Ag/37LRP expression and contributes to apoptosis resistance in gastric cancer.
Liu L; Zhang H; Sun L; Gao Y; Jin H; Liang S; Wang Y; Dong M; Shi Y; Li Z; Fan D
Int J Cancer; 2010 Aug; 127(4):820-9. PubMed ID: 19998339
[TBL] [Abstract][Full Text] [Related]
3. Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells.
Kwon DS; Kwon CH; Kim JH; Woo JS; Jung JS; Kim YK
Eur J Cell Biol; 2006 Nov; 85(11):1189-99. PubMed ID: 16860436
[TBL] [Abstract][Full Text] [Related]
4. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.
Miranda MB; McGuire TF; Johnson DE
Leukemia; 2002 Apr; 16(4):683-92. PubMed ID: 11960350
[TBL] [Abstract][Full Text] [Related]
5. The Function of SDF-1-CXCR4 Axis in SP Cells-Mediated Protective Role for Renal Ischemia/Reperfusion Injury by SHH/GLI1-ABCG2 Pathway.
Ge G; Zhang H; Li R; Liu H
Shock; 2017 Feb; 47(2):251-259. PubMed ID: 27454381
[TBL] [Abstract][Full Text] [Related]
6. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
7. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of extracellular signal-regulated kinases 1/2 provides neuroprotection in spinal cord ischemia/reperfusion injury in rats: relationship with the nuclear factor-kappaB-regulated anti-apoptotic mechanisms.
Lu K; Liang CL; Liliang PC; Yang CH; Cho CL; Weng HC; Tsai YD; Wang KW; Chen HJ
J Neurochem; 2010 Jul; 114(1):237-46. PubMed ID: 20403072
[TBL] [Abstract][Full Text] [Related]
9. Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway.
Fukazawa H; Noguchi K; Murakami Y; Uehara Y
Mol Cancer Ther; 2002 Mar; 1(5):303-9. PubMed ID: 12489846
[TBL] [Abstract][Full Text] [Related]
10. NO donor and MEK inhibitor synergistically inhibit proliferation and invasion of cancer cells.
Furuhashi S; Sugita H; Takamori H; Horino K; Nakahara O; Okabe H; Miyake K; Tanaka H; Beppu T; Baba H
Int J Oncol; 2012 Mar; 40(3):807-15. PubMed ID: 22025280
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the MEK/ERK signaling pathway blocks a subset of B cell responses to antigen.
Richards JD; Davé SH; Chou CH; Mamchak AA; DeFranco AL
J Immunol; 2001 Mar; 166(6):3855-64. PubMed ID: 11238629
[TBL] [Abstract][Full Text] [Related]
12. Fcgamma receptor signaling in primary human microglia: differential roles of PI-3K and Ras/ERK MAPK pathways in phagocytosis and chemokine induction.
Song X; Tanaka S; Cox D; Lee SC
J Leukoc Biol; 2004 Jun; 75(6):1147-55. PubMed ID: 14982949
[TBL] [Abstract][Full Text] [Related]
13. Activation of ERK accelerates repair of renal tubular epithelial cells, whereas it inhibits progression of fibrosis following ischemia/reperfusion injury.
Jang HS; Han SJ; Kim JI; Lee S; Lipschutz JH; Park KM
Biochim Biophys Acta; 2013 Dec; 1832(12):1998-2008. PubMed ID: 23851027
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer resistance protein/ABCG2 is differentially regulated downstream of extracellular signal-regulated kinase.
Imai Y; Ohmori K; Yasuda S; Wada M; Suzuki T; Fukuda K; Ueda Y
Cancer Sci; 2009 Jun; 100(6):1118-27. PubMed ID: 19514121
[TBL] [Abstract][Full Text] [Related]
15. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP).
Meyer zu Schwabedissen HE; Grube M; Dreisbach A; Jedlitschky G; Meissner K; Linnemann K; Fusch C; Ritter CA; Völker U; Kroemer HK
Drug Metab Dispos; 2006 Apr; 34(4):524-33. PubMed ID: 16415123
[TBL] [Abstract][Full Text] [Related]
17. MAPK and JAK-STAT signaling pathways are involved in the oxidative stress-induced decrease in expression of surfactant protein genes.
Park SK; Dahmer MK; Quasney MW
Cell Physiol Biochem; 2012; 30(2):334-46. PubMed ID: 22739240
[TBL] [Abstract][Full Text] [Related]
18. Side population in human non-muscle invasive bladder cancer enriches for cancer stem cells that are maintained by MAPK signalling.
Hepburn AC; Veeratterapillay R; Williamson SC; El-Sherif A; Sahay N; Thomas HD; Mantilla A; Pickard RS; Robson CN; Heer R
PLoS One; 2012; 7(11):e50690. PubMed ID: 23226356
[TBL] [Abstract][Full Text] [Related]
19. MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis.
Jo SK; Cho WY; Sung SA; Kim HK; Won NH
Kidney Int; 2005 Feb; 67(2):458-66. PubMed ID: 15673293
[TBL] [Abstract][Full Text] [Related]
20. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
